Brand Intelligence Graphcompany
Company Overview
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
Business Model & Competitive Advantage
Incyte's oncology and inflammation biopharmaceutical model creates competitive advantages through the regulatory exclusivity and clinical depth of the JAK inhibitor franchise in hematology: ruxolitinib's decade-plus of post-marketing data across myelofibrosis, polycythemia vera, acute GVHD, and chronic GVHD creates a clinical database that competitor JAK inhibitors (fedratinib from Bristol Myers Squibb, pacritinib from CTI BioPharma) cannot replicate without years of comparative clinical experience — giving oncologists a comfort level with ruxolitinib's safety profile in fragile hematology patients that is difficult to unseat. The Opzelura dermatology franchise (topical ruxolitinib cream — the only FDA-approved topical JAK inhibitor for atopic dermatitis and the first approved treatment for non-segmental vitiligo) creates a second revenue pillar beyond hematology, as dermatologists adopt the cream for patients with moderate-to-severe atopic dermatitis who failed topical steroids and non-steroidal topical agents. The Novartis royalty stream (approximately $700-800 million annually from Novartis's international Jakavi sales) provides high-margin income that diversifies Incyte's revenue beyond US Jakafi product sales.
Competitive Landscape 2025–2026
In 2025, Incyte competes in hematology/oncology and dermatology JAK inhibitor therapeutics against Bristol Myers Squibb (NYSE: BMY, Inrebic/fedratinib for myelofibrosis), Pfizer (NYSE: PFE, Xeljanz/tofacitinib for rheumatoid arthritis and inflammatory diseases), and Eli Lilly (NYSE: LLY, Olumiant/baricitinib for rheumatoid arthritis and atopic dermatitis) for JAK inhibitor prescribing in myelofibrosis, polycythemia vera, atopic dermatitis, and emerging inflammatory indications. The Jakafi (ruxolitinib) loss of exclusivity timeline — US patents protecting ruxolitinib expire in 2028, triggering generic competition — creates urgency for Incyte to grow Opzelura dermatology revenues, axatilimab GVHD revenues, and pipeline product launches before generic ruxolitinib enters the myelofibrosis market. Opzelura's atopic dermatitis market penetration (competing with AbbVie's Rinvoq oral upadacitinib and Pfizer's Cibinqo oral abrocitinib — both oral JAK inhibitors with broader efficacy but more systemic side effects than topical ruxolitinib) positions Incyte's topical therapy for patients and physicians preferring local anti-inflammatory treatment over systemic JAK inhibition. The 2025 strategy focuses on axatilimab chronic GVHD launch ramp (Niktimvo — first CSF-1R inhibitor approved for cGVHD), Opzelura non-segmental vitiligo DTC patient awareness campaigns, and pipeline progression for povorcitinib in dermatology indications.
The Incyte Story
Founders
Recent Activity
View all →Incyte Instagram feed 12May 2026 incyte_admin Thu, 05/14/2026 - 09:02
Incyte instagram feed 24 April 2026 incyte_admin Thu, 05/14/2026 - 09:00
incyte instagram feed 15 april 2026 incyte_admin Thu, 05/14/2026 - 08:59
incyte instagram 8 april 2026 incyte_admin Thu, 05/14/2026 - 08:55
incyte_instagram_feed_april012026 incyte_admin Thu, 05/14/2026 - 08:46
SUKETU (SUKY) UPADHYAY incyte_admin Mon, 05/04/2026 - 00:00 Suketu (Suky) Upadhyay joined Incyte in 2026 and is Executive Vice President and Chief Financial Officer (CFO). As a key member of the Executive Leadership Team, he is responsible for leading the Company’s global finance organization. Mr. Upadhyay has extensive experience in the healthcare sector and a proven track record of strengthening global financial operations and leading transformations that drive significant value. Prior to joining Incyte, Mr. Upadhyay served as Executive Vice President and Chief Financial Officer at Zimmer Biomet, a leading manufacturer of orthopedic solutions. Prior to that, he held senior finance leadership roles at several major pharmaceutical companies, including Senior Vice President of Global Financial Operations at Bristol Myers Squibb and Executive Vice President and Chief Financial Officer at Endo International. Mr. Upadhyay also served as Interim Chief Financial Officer and Chief Accounting
Proxy Statement filed 2026-04-28
Material Event filed 2026-04-28
Quarterly Report filed 2026-04-28
Material Event filed 2026-03-30
Material Event filed 2026-03-26
insta feed incyte 6 2026 incyte_admin Thu, 03/19/2026 - 14:32
Company Timeline
Major milestones in Incyte's journey
Leadership Team
Meet the leaders behind Incyte
Bill Meury
Bill Meury was appointed President and CEO of Incyte in June 2025, succeeding Hervé Hoppenot. He previously served as CEO of Anthos Therapeutics (acquired by Novartis in April 2025) and led Karuna Therapeutics until its merger with Bristol Myers Squibb in March 2024. Earlier in his career, Meury was Executive Vice President and Chief Commercial Officer at Allergan, bringing extensive experience in commercial strategy and business development.
Hervé Hoppenot
Hervé Hoppenot joined Incyte in 2014 as President and CEO and was appointed Chairman of the Board in 2015. During his 11-year tenure, he transformed Incyte into a global biopharmaceutical leader, overseeing the expansion of Jakafi into multiple indications, the launch of Opzelura, and numerous strategic acquisitions. He now serves as an advisor to the CEO through 2025.
Pablo J. Cagnoni, M.D.
Dr. Cagnoni joined Incyte in 2023 to lead all R&D efforts across Oncology, Hematology, Inflammation, and Autoimmunity portfolios. He previously served as CEO of Laronde and held leadership roles at Rubius Therapeutics, Tizona Therapeutics, Onyx Pharmaceuticals, and Novartis Oncology. Throughout his career, Dr. Cagnoni has advanced development of over 20 life-changing medicines. He earned his medical degree from University of Buenos Aires and completed fellowships at Mount Sinai Medical Center and University of Colorado.
Christiana Stamoulis
Christiana Stamoulis served as Executive Vice President and CFO from February 2019 to September 2025, bringing over 20 years of biotechnology industry experience. She previously held senior roles at Vertex Pharmaceuticals as SVP of Corporate Strategy and Business Development, and spent 15 years in investment banking at Citigroup and Goldman Sachs. She holds two Bachelor of Science degrees from MIT and an MBA from MIT Sloan School of Management.
Lee Heeson
Lee Heeson joined Incyte in October 2024 to lead international operations and commercial strategy across Europe, Asia, and other global markets. He brings extensive pharmaceutical industry experience in expanding international market presence and driving commercial excellence.
Matteo Trotta
Matteo Trotta joined Incyte in 2024 to lead the U.S. Dermatology business unit, overseeing the commercial strategy for Opzelura and future dermatology pipeline products. His appointment reflects Incyte's strategic focus on building its dermatology franchise.
Key Differentiators
Market Leader
Incyte is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $3.9B in revenue, Incyte operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Incyte with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Incyte? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Incyte Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Incyte vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →